Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups.

Krauth MT, Alpermann T, Bacher U, Eder C, Dicker F, Ulke M, Kuznia S, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S.

Leukemia. 2015 Mar;29(3):660-7. doi: 10.1038/leu.2014.243. Epub 2014 Aug 11.

PMID:
25110071
2.

Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.

Schnittger S, Bacher U, Alpermann T, Reiter A, Ulke M, Dicker F, Eder C, Kohlmann A, Grossmann V, Kowarsch A, Kern W, Haferlach C, Haferlach T.

Haematologica. 2012 Dec;97(12):1890-4. doi: 10.3324/haematol.2012.065375. Epub 2012 Jun 24.

3.

Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia.

Schnittger S, Bacher U, Haferlach T, Wendland N, Ulke M, Dicker F, Grossmann V, Haferlach C, Kern W.

Blood. 2012 Mar 29;119(13):3151-4. doi: 10.1182/blood-2011-10-383323. Epub 2012 Feb 13.

PMID:
22331186
4.

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.

Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W, Haferlach T.

Blood. 2010 Dec 16;116(25):5486-96. doi: 10.1182/blood-2010-02-267955. Epub 2010 Aug 30.

PMID:
20805365

Supplemental Content

Support Center